Spring / Summer 2023 | A New Era 3
“ This new tool allows us to define Parkinson ’ s disease objectively and biologically — with implications for every aspect of Parkinson ’ s research and care .”
Today — with this discovery — we are closer than ever to this future state . Yet , we ’ re also at the starting line to take steps to advance this tool further , moving it into clinical trials and helping doctors and patients understand more about Parkinson ’ s onset , stages , variability of symptoms and prognosis . As one chapter closes , another begins . And as we pause for a moment to acknowledge our progress , we stand ready to be bold again , as we always have been , seeking the next significant return on our investment in life-transforming research .
I know we will achieve this future state thanks to you — our community of patients and families , and especially the thousands of you who have volunteered to take part in research . It is no exaggeration to say our community is critical to speeding progress , piecing together the Parkinson ’ s puzzle and helping move the dial on a cure .
Our close relationships with patients and families are indispensable to our work . Your engagement alone positions us to understand the unmet needs of those living with the disease — an understanding that we then work to bring to researchers on the front lines of Parkinson ’ s science . You have helped us build trust and credibility with researchers . And we will never stop working to bring these two communities together in service of accelerating better treatments and a cure .
With gratitude ,
Debi Brooks , CEO and Co-Founder
“ Validation of this biomarker launches a new , biological era in Parkinson ’ s research .”
— Ken Marek , MD , principal investigator , the Parkinson ’ s Progression Markers Initiative